PD-1/PDL-1 inhibitors have revolutionized cancer treatment, especially in lung cancer. Despite their efficacy, a new spectrum of side effects, called immune-related adverse events, may occur and their management could be difficult. Gigantomastia, a rare condition characterized by excessive growth of the breasts, has been associated with some drugs, but no correlation with immunotherapy has ever been reported. Here, we report the case of a possible immune-related gigantomastia.
Immune-related gigantomastia: a case study / A. Lozito, M.G.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 15:13(2023 Sep), pp. 1001-1007. [10.2217/imt-2023-0056]
Immune-related gigantomastia: a case study
G. PelosiPenultimo
;
2023
Abstract
PD-1/PDL-1 inhibitors have revolutionized cancer treatment, especially in lung cancer. Despite their efficacy, a new spectrum of side effects, called immune-related adverse events, may occur and their management could be difficult. Gigantomastia, a rare condition characterized by excessive growth of the breasts, has been associated with some drugs, but no correlation with immunotherapy has ever been reported. Here, we report the case of a possible immune-related gigantomastia.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Gigantomastia 2023.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
5.8 MB
Formato
Adobe PDF
|
5.8 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
